LR Health & Beauty SE, a leading European social commerce company for nutritional supplements and beauty products, has published its final annual report for 2025, confirming the preliminary sales and earnings figures. The LR Group generated sales of EUR 277.1 million in 2025, down from EUR 289.2 million in 2024. Reported EBITDA fell to EUR 16.5 million from EUR 27.3 million in the prior year, impacted by one-off effects from the reorganization of the financing structure. Normalized EBITDA for 2025 was EUR 22.5 million, compared to EUR 32.6 million in 2024.
CEO Jörg Körfer commented, “The 2026 financial year is a transitional year for LR, during which we have laid the groundwork – both financially and strategically – for sustainable business growth and performance. The newly established financing structure gives us the momentum we need to continue to consistently pursue the initiatives we have launched in production, logistics and sales in the second half of the year.” He emphasized the company's commitment to working closely with partners and expanding international relationships.
As part of its strategic measures, LR is investing over 2 million euros in a new, high-performance production line, centralizing the manufacture of its 5in1 product category entirely at its Ahlen site. This includes the established products LR 5in1 Beauty Elixir and LR 5in1 Men’s Shot. The new facility is designed to have an annual capacity of up to 40 million units and will also enable further product innovations in modern nutritional supplement concepts.
This investment underscores LR's focus on expanding in-house production as a key strategic pillar. The full 2025 Annual Report is now available on the company’s website at ir.lrworld.com.
The LR Group, headquartered in Ahlen, Germany, produces and distributes high-quality nutritional supplements and cosmetic products in 32 countries. With a history dating back to 1985, the company has built a strong reputation in social commerce, leveraging digital tools like the “LR neo” dashboard to support its international partnership.
These developments come at a time when the biohacking and wellness industries are increasingly focused on product quality and innovation. LR's investment in production capacity could signal a trend toward vertical integration and enhanced quality control, which may resonate with consumers seeking reliable and effective nutritional supplements. The company's commitment to centralizing production and expanding its product line may also impact the competitive landscape by setting new standards for efficiency and product development.
